This clinical trial is focused on studying the effects of a medication called Dobutamine in patients with a condition known as septic cardiomyopathy. Septic cardiomyopathy occurs when the heart’s ability to pump blood is weakened due to sepsis, a severe infection that spreads throughout the body. The study aims to understand how Dobutamine, when used alongside standard treatments, affects the functioning of organs in patients experiencing septic shock, a serious complication of sepsis where blood pressure drops to dangerously low levels.
Participants in the study will receive either Dobutamine or a placebo, which is a substance with no active medication. The treatment will be administered through an intravenous infusion, meaning it will be delivered directly into the bloodstream. The study will monitor the participants over a period of several days to observe changes in their health, particularly focusing on how their organs are functioning. This includes looking at heart function, blood pressure, and other vital signs to determine the impact of the treatment.
The goal of the study is to gather information on whether Dobutamine can help improve outcomes for patients with septic cardiomyopathy by supporting their heart and other organs during a critical time. The findings from this research could potentially lead to better treatment strategies for managing septic shock and its effects on the heart. Participants will be closely monitored by medical professionals throughout the study to ensure their safety and well-being.
France 